San Diego-based Engrail Therapeutics launched with $32 million in a Series A financing round that was solely funded by Nan Fung Life Sciences (NFLS).
Signals Analytics’ online COVID-19 Playbook is an analytics platform that uses external data that uncover trends and predictive insights.
Austria-based OncoOne launched with a Series A financing round worth 13 million euros ($14.26 million).
The novel coronavirus (2019-nCoV), which originated in Wuhan, China in December 2019, has been making headlines left and right as the ticker climbs of those who have been sickened and died from the virus.
GlaxoSmithKline outlined a plan to split the company into two entities over the next two years.
In drug development, assets are often aimed at a specific disease target or pathway, similar to a bullet fired from a gun. The idea of going after one precise target though, may not be the best solution for treating the totality of diseases, though. What may be more effective in the long run, is hitting a disease along multiple target lines. That is the idea at Cambridge, Mass.-based Immuneering.
Personal Genome Diagnostics Inc. (PGDx) – a leader in cancer genomics – is partnering with Eisai Co. Ltd. to develop a comprehensive liquid biopsy biomarker discovery solution for oncology, to be used by Eisai researchers at their Tsukuba Research Laboratory.
Biomedical engineers at the University of Minnesota conducted a first-of-its-kind study on molecular interactions.
Dozens of drugmakers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an approach that has long fallen short of its promise, an analysis compiled for Reuters shows.
Blackstone Group Inc. is investing $400 million in a joint venture with Swiss drug company Ferring that is working on an experimental gene therapy for bladder cancer, the private equity giant’s largest-ever bet on drug development.
